Global CNS Therapeutics Market Growth (Status and Outlook) 2023-2029

Global CNS Therapeutics Market Growth (Status and Outlook) 2023-2029

Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).

LPI (LP Information)' newest research report, the “CNS Therapeutics Industry Forecast” looks at past sales and reviews total world CNS Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected CNS Therapeutics sales for 2023 through 2029. With CNS Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CNS Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global CNS Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CNS Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CNS Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CNS Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CNS Therapeutics.

The global CNS Therapeutics market size is projected to grow from US$ 74640 million in 2022 to US$ 104740 million in 2029; it is expected to grow at a CAGR of 5.0% from 2023 to 2029.

Mental health segment accounted for the largest market share in 2016. It is expected to retain its dominance over the forecast period owing to developing therapeutic options for mental diseases such as personality disorders and binge eating disorders. This segment is followed by degenerative disorders segment. There is growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and nongovernment organizations, such as Alzheimer’s and Related Disorders Society of India. These organizations conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental disorders.

This report presents a comprehensive overview, market shares, and growth opportunities of CNS Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Neurodegenerative Diseases
Mood Disorders
Schizophrenia
Autism
Depression

Segmentation by application
Hospital Use
Clinic Use
Household
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Janssen Pharmaceuticals
Allergan
Lundbeck
Teva
Camber Pharmaceuticals
Zhejiang Haisen Pharmaceutical
Jewim Pharmaceutical
Cipla
Merck Sharp & Dohme Corp.
Eli Lilly
GlaxoSmithKline
Novartis
LUPIN
ZYDUS PHARMS
Biogen
Otsuka Pharmaceutical
Astra Zeneca
Takeda

Please note: The report will take approximately 2 business days to prepare and deliver.